Viewpoint

Cynics say it merely wants to curry favour with the European Union, but Intel’s revamp of its labs is a convincing model for corporate engagement in R&D, writes Nuala Moran.

Everyone’s strapped for cash – except pharma. But the latest spending spree is no more of a fix for expiring patents than botox is for ageing skin, writes Nuala Moran.

London 2012 will leave no lasting innovation legacy unless the UK gets serious about investing in sports science, writes Pete Wrobel.

Nursing the global financial system back to health will not be the solution. Let science be the source of the green shoots of recovery, writes Nuala Moran.

Science is about to get back into Washington’s good books – and not before time, says Science|Business’s Nuala Moran.

The UK’s new £1 billion start-up fund should support entrepreneurs with immediate plans to bring a product into the market, not long-term projects to commercialise new research, says NESTA’s Sami Mahroum.

The French Presidency made headway on the Small Business Act, but other matters, notably patent reform, were run off the rails by the financial crisis, says Science|Business’s Paul Meller

Depending who you ask, the long-awaited and final ruling on the University of Wisconsin’s WARF patent is either a landmark decision or signifies nothing.

David Alcock of the Patent Attorneys D Young & Co addresses concerns that a recent patent judgment undermines the concept of evergreening, even though Tate & Lyle’s US patents to Sucralose are valid.

A new “Bretton Woods” should lead to the creation of a World Knowledge Fund with a mission to bridge the global knowledge gap.